Literature DB >> 35108465

Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant.

Roby P Bhattacharyya1, William P Hanage1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35108465     DOI： 10.1056/NEJMp2119682

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  30 in total

Review 1.  Pathogenesis of pneumonia and acute lung injury.

Authors:  Matthew E Long; Rama K Mallampalli; Jeffrey C Horowitz
Journal:  Clin Sci (Lond)       Date:  2022-05-27       Impact factor: 6.876

2.  Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.

Authors:  Joseph A Lewnard; Vennis X Hong; Manish M Patel; Rebecca Kahn; Marc Lipsitch; Sara Y Tartof
Journal:  Nat Med       Date:  2022-06-08       Impact factor: 87.241

3.  Excess Mortality in Massachusetts During the Delta and Omicron Waves of COVID-19.

Authors:  Jeremy Samuel Faust; Chengan Du; Chenxue Liang; Katherine Dickerson Mayes; Benjamin Renton; Kristen Panthagani; Harlan M Krumholz
Journal:  JAMA       Date:  2022-07-05       Impact factor: 157.335

4.  GenomeBits insight into omicron and delta variants of coronavirus pathogen.

Authors:  Enrique Canessa; Livio Tenze
Journal:  PLoS One       Date:  2022-07-11       Impact factor: 3.752

5.  Decreased Risk of Coronavirus Disease 2019-Related Hospitalization Associated With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2.

Authors:  Jessica P Ridgway; Samuel Tideman; Bill Wright; Ari Robicsek
Journal:  Open Forum Infect Dis       Date:  2022-06-15       Impact factor: 4.423

Review 6.  Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.

Authors:  William R Strohl; Zhiqiang Ku; Zhiqiang An; Stephen F Carroll; Bruce A Keyt; Lila M Strohl
Journal:  BioDrugs       Date:  2022-04-27       Impact factor: 7.744

7.  Impact of Omicron surge in community setting in greater Paris area.

Authors:  Aurélien Dinh; Lotfi Dahmane; Mehdi Dahoumane; Xavier Masingue; Patrick Jourdain; François-Xavier Lescure
Journal:  Clin Microbiol Infect       Date:  2022-02-16       Impact factor: 13.310

8.  SARS-CoV-2 Omicron (B.1.1.529) Variant: Corticosteroids Treatment/Respiratory Coinfection.

Authors:  Zeev Elkoshi
Journal:  Front Immunol       Date:  2022-03-03       Impact factor: 7.561

9.  Estimation of Serial Interval and Reproduction Number to Quantify the Transmissibility of SARS-CoV-2 Omicron Variant in South Korea.

Authors:  Dasom Kim; Sheikh Taslim Ali; Sungchan Kim; Jisoo Jo; Jun-Sik Lim; Sunmi Lee; Sukhyun Ryu
Journal:  Viruses       Date:  2022-03-04       Impact factor: 5.048

10.  Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City.

Authors:  Alberto Cedro-Tanda; Laura Gómez-Romero; Guillermo de Anda-Jauregui; Dora Garnica-López; Yair Alfaro-Mora; Sonia Sánchez-Xochipa; Eulices F García-García; Alfredo Mendoza-Vargas; Emmanuel J Frías-Jiménez; Bernardo Moreno; Abraham Campos-Romero; José L Moreno-Camacho; Jonathan Alcantar-Fernández; Jesús Ortíz-Ramírez; Mariana Benitez-González; Roxana Trejo-González; Daniel Aguirre-Chavarría; Marcela E Núñez-Martínez; Laura Uribe-Figueroa; Ofelia Angulo; Rosaura Ruiz; Alfredo Hidalgo-Miranda; Luis A Herrera
Journal:  Viruses       Date:  2022-03-06       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.